Jackson, SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis
2002; 23: 687–696.
Gewillig, M. The Fontan circulation. Heart
2005; 91: 839–846.
Narkewicz, MR, Sondheimer, HM, Ziegler, JW, et al. Hepatic dysfunction following the Fontan procedure. J Pediatr Gastroenterol Nutr
2003; 36: 352–357.
Rychik, J, Veldtman, G, Rand, E, et al. The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol
2012; 33: 1001–1012.
Wu, FM, Ukomadu, C, Odze, RD, et al. Liver disease in the patient with Fontan circulation. Congenit Heart Dis
2011; 6: 190–201.
Baek, JS, Bae, EJ, Ko, JS, et al. Late hepatic complications after Fontan operation; non-invasive markers of hepatic fibrosis and risk factors. Heart
2010; 96: 1750–1755.
Gentles, TL, Gauvreau, K, Mayer, JE Jr., et al. Functional outcome after the Fontan operation: factors influencing late morbidity. J Thorac Cardiovasc Surg
1997; 114: 392–403; discussion 404–395.
Beghetti, M. Fontan and the pulmonary circulation: a potential role for new pulmonary hypertension therapies. Heart
2012; 96: 911–916.
Goldberg, DJ, Shaddy, RE, Ravishankar, C, et al. The failing Fontan: etiology, diagnosis and management. Expert Rev Cardiovasc Ther
2011; 9: 785–793.
Reinhardt, Z, Uzun, O, Bhole, V, et al. Sildenafil in the management of the failing Fontan circulation. Cardiol Young
2010; 20: 522–525.
Uzun, O, Wong, JK, Bhole, V, et al. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg
2006; 82: e39–e40.
Walker, DK, Ackland, MJ, James, GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica
1999; 29: 297–310.
Muirhead, GJ, Wilner, K, Colburn, W, et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol
2002; 53 (Suppl 1): 21S–30S.
Barst, RJ, Ivy, DD, Gaitan, G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation
2011; 125: 324–334.
Hill, KD TR, Barker, P, Fleming, GA, et al. Sildenafil exposure and hemodynamic effect after stage II single ventricle surgery. Pediatr Crit Care Med
2014; 15: 28–34.
Hill, KD, Tunks, RD, Barker, PC, et al. Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. Pediatr Crit Care Med
2013; 14: 593–600.
Mukherjee, A, Dombi, T, Wittke, B, et al. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther
2009; 85: 56–63.
Muirhead, GJ, Rance, DJ, Walker, DK, et al. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol
2002; 53 (Suppl 1): 13S–20S.
Vachiery, JL, Huez, S, Gillies, H, et al. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol
2011; 71: 289–292.
Nichols, DJ, Muirhead, GJ, Harness, JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol
2002; 53 (Suppl 1): 5S–12S.
Marsot, A, Boulamery, A, Bruguerolle, B, et al. Population pharmacokinetic analysis during the first 2 years of life: an overview. Clin Pharmacokinet
2012; 51: 787–798.
Laughon, MM, Benjamin, DK Jr., Capparelli, EV, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol
2011; 4: 643–652.
Ku, LC, Smith, PB. Dosing in neonates: special considerations in physiology and trial design. Pediat Res
2015; 77(1-1): 2–9.
Valitalo, P, Ranta, VP, Hooker, AC, et al. Population pharmacometrics in support of analgesics studies. Acta Anaesthesiol Scand
2014; 58: 143–156.
Goldberg, DJ, French, B, McBride, MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation
2011; 123: 1185–1193.
Giardini, A, Balducci, A, Specchia, S, et al. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J
2008; 29: 1681–1687.